Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation.
about
Association between monocyte Fcgamma subclass expression and acute coronary syndromeHormonal influence on coenzyme Q(10) levels in blood plasmaHeat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexes in macrophagesModel IgG monoclonal autoantibody-anti-idiotype pair for dissecting the humoral immune response to oxidized low density lipoproteinClinical significance of the humoral immune response to modified LDL.Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress.Immunomodulation of atherosclerosis: myth and reality.Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic miceYou are right too!Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation.Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesisAnti-beta 2-glycoprotein I autoantibodies and atherosclerosis.Lipoprotein autoantibodies: measurement and significance.Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease.Accelerated atherosclerosis in ApoE deficient lupus mouse models.Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.Atherogenesis and the humoral immune response to modified lipoproteinsOxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release.OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages.Immune and inflammatory mechanisms in the development of atherosclerosis.Modified lipoproteins, cytokines and macrovascular disease in non-insulin-dependent diabetes mellitus.Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value.Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells.Autoimmune response to advanced glycosylation end-products of human LDL.Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis.Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy.Detection of Circulating Auto-Antibodies Against Ribosylated-LDL in Diabetes Patients.LDL immune complexes stimulate LDL receptor expression in U937 histiocytes via extracellular signal-regulated kinase and AP-1.
P2860
Q24804925-F1A7F16E-4B7E-4AF6-B18D-E5C30336BA5DQ27025462-80E39840-6AB9-4C3F-9ED4-9CDCC3AD6409Q30494525-A5FC49A2-6FF7-4878-B1F7-F615BDF29B2FQ31055400-6872C4BD-BC2F-46BC-86B1-888DCC24377DQ33598770-3CF260C8-74F3-4AE7-BC69-DCACA6E480E7Q33686991-7B0B37C9-304D-431F-8CD0-EA0D7C074F73Q33890414-9C4813B3-86D6-4239-9C3A-59EAD2F93AA2Q33905765-45C3E35D-4F8D-428B-BD5E-DAFC32CEC499Q33905863-043457D8-182C-49E2-BD55-9089B020A914Q34072528-87F22B8A-56F1-490B-A375-ADF69D50D3F6Q34390132-B8B24406-4A33-4A62-A6AD-58CB67B89DB9Q34538168-E30B8717-1AF4-4BA6-9B1A-1450062268E2Q34542912-6DA4F7C9-9AE7-48A0-8EB7-0A31A808EB18Q34737721-446F148A-2FE8-465C-AD35-50622BAA0A8AQ34790028-39BF2786-EADC-4990-B714-51A73520BC5AQ35140009-FC67CDE8-379B-4625-B87B-D9369059486EQ35539166-9B2540B5-DBE9-45E7-BA6A-07D96143CA67Q36362707-F006AB49-4B3D-4902-B5E2-6FC2D16864F8Q36766008-950D31DF-625D-4C4A-9A63-3837DD10DB11Q37012519-6000345D-35EA-4FD7-A90C-57C8DD00C664Q37021490-B76590BD-39B9-4EB2-A88B-8875623D3EE0Q37584378-8E624D20-DC06-4F23-BC8B-FD5A92FFA8CFQ39413836-66A7BD2F-F2D9-46BD-A3FD-307D49A58E91Q40262380-2E890CA0-973D-4F28-8A18-FE94C0B09381Q40872807-67ED5A20-BEE3-409D-AC36-E24DEC5696F3Q41156145-A57DDAE7-ECB5-472E-BC91-99301D707E7BQ41915428-C116A887-0DFB-41AA-9230-15BA0F668C0CQ43193872-F8F5D171-4EFC-4F84-AEA6-3C25AF562C84Q44300103-C671D3E5-E1ED-43DF-BA42-37A6772E36DFQ46495543-95B7C044-B3A8-4B54-9E9D-7D5ED1DC5B00Q51390737-F5014C1E-B350-4F4F-AB6C-883FA9B1AD74Q51550442-D510134A-4C3A-40BE-97C3-D789F61D1EA4Q54775083-416A5D16-82D7-4F1E-AA3F-309D789A8E25
P2860
Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Low density lipoprotein metabo ...... hanism of foam cell formation.
@ast
Low density lipoprotein metabo ...... hanism of foam cell formation.
@en
type
label
Low density lipoprotein metabo ...... hanism of foam cell formation.
@ast
Low density lipoprotein metabo ...... hanism of foam cell formation.
@en
prefLabel
Low density lipoprotein metabo ...... hanism of foam cell formation.
@ast
Low density lipoprotein metabo ...... hanism of foam cell formation.
@en
P2093
P2860
P356
P1476
Low density lipoprotein metabo ...... hanism of foam cell formation.
@en
P2093
G T Virella
H C Stevenson
M F Lopes-Virella
R L Griffith
P2860
P304
P356
10.1084/JEM.168.3.1041
P407
P577
1988-09-01T00:00:00Z